跳至主要内容
临床试验/NCT03723135
NCT03723135Approved For Marketing不适用

Expanded Access for CC-486

Celgene1 个研究点 分布在 1 个国家开始时间: 2018年10月29日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
Approved For Marketing
发起方
Celgene
试验地点
1

研究概览

简要总结

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult patients with documented acute myelogenous leukemia (AML) in their first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, who seek treatment with CC-486 as monotherapy to maintain their CR or CRi.

排除标准

  • •Patients with AML in CR/CRi who plan to proceed to or are waiting for a bone marrow transplant
  • •Patients who have received a bone marrow transplant for the treatment of AML
  • •Treatment of AML patients with relapse or refractory disease
  • •Pregnant or breast-feeding females
  • •Patient meets enrollment criteria and can participate in a disease-specific clinical trial

研究者

发起方
Celgene
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验